Acitretin
| Evidence Level: L3 | Predicted Indications: 4 |
Table of Contents
Acitretin: From Its Approved Indication to Acne (Disease)
One-Sentence Summary
Acitretin is an oral second-generation retinoid marketed in Canada, but the data compiled for this report do not include its approved indication text. The TxGNN model predicts it may be effective for acne (disease), with 1 clinical trial and 18 publications currently touching on this direction. Most of this evidence concerns hidradenitis suppurativa (acne inversa), not classic acne vulgaris.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the compiled data (Health Canada licence records contain no indication text) |
| Predicted New Indication | Acne (disease) |
| TxGNN Prediction Score | 0.9994 |
| Evidence Level | L3 |
| Canada Market Status | Marketed (marketed DINs: 6 of 6) |
| Number of DINs | 6 (marketed: 6) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on known information, acitretin is a second-generation oral retinoid that modulates keratinocyte differentiation and proliferation and has anti-inflammatory effects. The literature describes its main success in psoriasis and other hyperkeratotic skin disorders.
Retinoids reduce sebaceous gland activity and follicular hyperkeratinization, which are core processes in acne and in follicular occlusion diseases such as hidradenitis suppurativa (acne inversa). This gives the prediction a plausible mechanistic basis.
An important caveat: most of the supporting evidence concerns hidradenitis suppurativa and related follicular disorders, not acne vulgaris. For acne vulgaris, isotretinoin remains the standard retinoid. The prediction is therefore best viewed as a research question rather than a ready-to-use new indication.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07708480 | Phase 4 | Completed | 70 | Randomized comparison of apremilast (30 mg twice daily) vs acitretin (25 mg twice daily) for 12 weeks in moderate-to-severe hidradenitis suppurativa; primary outcome IHS4. Results not provided. Relevance is moderate because the trial does not study acne vulgaris. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25640693 | 2015 | Guideline | J Eur Acad Dermatol Venereol | European S1 guideline for treating hidradenitis suppurativa/acne inversa |
| 33036809 | 2020 | Consensus Guideline | An Bras Dermatol | Brazilian consensus on oral isotretinoin; effective in acne, teratogenicity is the most serious risk |
| 40888828 | 2025 | Systematic Review | Am J Clin Dermatol | Ethnic differences in palmoplantar pustulosis |
| 29234829 | 2018 | Review | Hautarzt | Drug therapy of acne inversa, including antibiotics and TNF-α inhibitors |
| 9074840 | 1997 | Review | Drugs | Current and future use of retinoids in psoriasis, severe acne and related dermatoses |
| 8573927 | 1995 | Review | Dermatology | Retinoids and sebaceous gland activity; isotretinoin’s anti-acne effect is linked to inhibition of sebaceous activity |
| 20874789 | 2011 | Clinical study | Br J Dermatol | Long-term results of acitretin therapy for hidradenitis suppurativa |
| 12080949 | 2002 | Case Report | Cutis | Nodulocystic acne and hidradenitis suppurativa treated with acitretin |
| 41692081 | 2026 | Review | Clin Dermatol | Vitamin A and retinoids in dermatology, including acitretin |
| 28476075 | 2017 | Review (Cochrane) | Cochrane Database Syst Rev | Drugs for discoid lupus erythematosus |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02468840 | MINT-ACITRETIN | Not listed | Not listed |
| 02070847 | SORIATANE | Not listed | Not listed |
| 02468859 | MINT-ACITRETIN | Not listed | Not listed |
| 02466082 | TARO-ACITRETIN | Not listed | Not listed |
| 02070863 | SORIATANE | Not listed | Not listed |
A sixth licence (02466074, TARO-ACITRETIN) is also valid. All six licences are single-ingredient products.
Safety Considerations
- Teratogenicity: Acitretin is a known human teratogen, contraindicated in pregnancy, and requires contraception for up to 3 years after treatment.
- Other concerns noted in the evidence review: hepatotoxicity, and bone and growth effects in children.
- Knowledge-graph contraindication signals (from drug-disease links, not label text): liver failure, drug-induced liver injury, pancreatitis, hypertriglyceridemia, diabetes mellitus, diabetic ketoacidosis, obesity, anxiety and dysthymic disorders, substance abuse/dependence, pseudotumor cerebri, intracranial hypertension, vision disorders including night blindness, and hyperostosis.
- Drug Interactions (100 recorded; main ones listed):
- Major: doxycycline, minocycline, tetracycline, vitamin A
- Moderate: sulfonylureas (acetohexamide, chlorpropamide, glimepiride, glipizide, glyburide, tolazamide, tolbutamide) and naltrexone
Conclusion and Next Steps
Decision: Hold
Rationale: Support for acne specifically is thin. The only trial and most of the literature concern hidradenitis suppurativa, and isotretinoin is the established retinoid for acne vulgaris. Together with acitretin’s serious teratogenicity and long contraception requirement, the prediction should be treated as a research question for now.
To proceed, the following is needed:
- Health Canada package insert warnings, contraindications and approved indications (currently blocking safety screening)
- Mechanism of action data (e.g., from DrugBank)
- Results of NCT07708480, and controlled studies of acitretin in acne vulgaris itself
- A risk-benefit comparison against isotretinoin, including a pregnancy-prevention plan
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.